UroGen Pharma (NASDAQ:URGN) Price Target Cut to $3.00 by Analysts at The Goldman Sachs Group

UroGen Pharma (NASDAQ:URGN - Get Free Report) had its price objective reduced by analysts at The Goldman Sachs Group from $16.00 to $3.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. The Goldman Sachs Group's target price would indicate a potential downside of 24.18% from the stock's previous close.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a "neutral" rating on shares of UroGen Pharma in a report on Thursday. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of UroGen Pharma in a report on Thursday, May 8th. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price on the stock. Scotiabank initiated coverage on UroGen Pharma in a research report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price target on the stock. Finally, Guggenheim reaffirmed a "buy" rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.00.

UroGen Pharma Stock Performance

NASDAQ URGN traded down $0.21 during midday trading on Thursday, hitting $3.96. The company had a trading volume of 911,743 shares, compared to its average volume of 649,582. The firm has a fifty day simple moving average of $10.32 and a two-hundred day simple moving average of $10.78. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The stock has a market cap of $182.45 million, a price-to-earnings ratio of -1.25 and a beta of 0.66. UroGen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. Equities analysts forecast that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

Institutional Trading of UroGen Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC grew its stake in shares of UroGen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after purchasing an additional 5,140 shares during the period. KLP Kapitalforvaltning AS bought a new stake in UroGen Pharma in the 4th quarter valued at $59,000. Lazard Asset Management LLC bought a new stake in UroGen Pharma in the fourth quarter worth $67,000. GAMMA Investing LLC raised its position in shares of UroGen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new position in shares of UroGen Pharma in the 4th quarter valued at about $101,000. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.